Deferred Tax Assets, Operating Loss Carryforwards of Anebulo Pharmaceuticals, Inc. from 30 Jun 2021 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Anebulo Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 30 Jun 2021 to 30 Jun 2025.
  • Anebulo Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Jun 2025 was $5,149,067, a 38% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

Anebulo Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $5,149,067 +$1,410,365 +38% 30 Jun 2025 10-K 29 Sep 2025 2025 FY
Q2 2024 $3,738,702 +$871,842 +30% 30 Jun 2024 10-K 29 Sep 2025 2025 FY
Q2 2023 $2,866,860 +$1,023,685 +56% 30 Jun 2023 10-K 25 Sep 2024 2024 FY
Q2 2022 $1,843,175 +$1,346,004 +271% 30 Jun 2022 10-K 22 Sep 2023 2023 FY
Q2 2021 $497,171 30 Jun 2021 10-K 09 Sep 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.